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ABSTRACT 
A spiral phenomenon is sometimes noted in the plots of CO2 output (VCO2) against O2 
uptake (VO2) measured during cardiopulmonary exercise testing (CPX) in heart failure 
patients with oscillatory breathing. However, few data are available that elucidate the clinical 
significance of this phenomenon. Our group studied the prevalence of this phenomenon and 
its relation to cardiac and cardiopulmonary function. Among 2,263 cardiac patients who 
underwent CPX, 126 patients with a clear pattern of oscillatory breathing were identified. 
Cardiopulmonary indices were compared between patients who showed the spiral 
phenomenon (n=49) and those who did not (n=77). The amplitudes of VO2 and VCO2 
oscillations were higher and the phase difference between VO2 and VCO2 oscillations was 
longer in the patients with the spiral phenomenon than in those without it. Patients with the 
spiral phenomenon also had a lower left ventricular ejection fraction (43.4±21.4 vs. 
57.1±16.8 %, p<0.001) and a higher level of brain natriuretic peptide (637.2±698.3 vs. 
228.3±351.4 pg/mL, p=0.002). The peak VO2 was lower (14.5±5.6 vs. 18.1±6.3, p=0.002), 
the VE-VCO2 slope was higher (39.8±9.5 vs. 33.6±6.8, p<0.001), and PETCO2 both at rest 
and at peak exercise was lower in the patients with the spiral phenomenon than in those 
without it. In conclusion, the spiral phenomenon in the VCO2-versus-VO2 plot arising from 
the phase difference between VCO2 and VO2 oscillations reflects more advanced 
cardiopulmonary dysfunction in cardiac patients with oscillatory breathing. 
KEY WORDS: cardiopulmonary function, oscillatory breathing, exercise testing 
  
 
 
 Oscillatory breathing in cardiac patients, a characteristic breathing pattern alternating 
between hyperpnea and hypopnea, can be evaluated in detail by cardiopulmonary exercise 
testing (CPX) [1]. Several valuable indices are obtained from CPX, including the peak O2 
uptake (VO2), the slope of the increase in ventilation (VE) versus the increase in CO2 output 
(VCO2) (VE-VCO2 slope), and the anaerobic threshold (AT). During incremental exercise 
below the AT, VCO2 increases approximately linearly with VO2, and its slope is theoretically 
1.0 or slightly less [2]. The slope above the AT becomes greater than 1.0, because lactic acid 
is buffered by bicarbonate, resulting in the formation of carbonic acid, which dissociates to 
water and CO2 [2]. A peculiar spiral (vortex) phenomenon progressing in a counterclockwise 
direction is sometimes recognized in the plot of VCO2 against VO2 during CPX in heart 
failure patients with oscillatory breathing [3]. In the present study we determined how 
frequently the spiral phenomenon can be observed during CPX in cardiac patients with 
oscillatory breathing and evaluated whether this phenomenon is related to impaired 
cardiopulmonary function.  
 
METHODS 
 The subjects for this study were 2,263 consecutive cardiac patients who underwent 
CPX at the Cardiovascular Institute for the evaluation of exercise capacity and/or severity of 
heart failure between January 2010 and December 2013. By visual observation, we identified 
all of subjects who manifested at least three consecutive cycles of clear ventilatory 
oscillations during the period from the beginning of warm-up exercise until the end of 
  
 
 
incremental exercise. After determining the amplitude (difference between the peak and 
nadir) of each VE oscillation, we calculated the percentage amplitude by dividing the 
amplitude by the mean VE during each oscillation and then calculated the mean value of all 
oscillations. Thereafter, we selected 126 subjects whose amplitudes were greater than 25 % of 
the mean VE, based on the report from Murphy et al. [4]. The research protocol was approved 
by the human subjects committee of the Cardiovascular Institute. The patients were apprised 
of the purposes and risks of the study, and all of them gave their informed consent. 
 A symptom-limited incremental exercise test was performed using an upright, 
electromagnetically braked cycle ergometer (Strength Ergo 8; Mitsubishi Electric 
Engineering Co., Ltd., Tokyo, Japan). The exercise test began with a 4-min rest on the 
ergometer followed by a 4-min warm-up at 0 W or 20 W at 60 rpm. The load was then 
increased incrementally by 1 W every 6 seconds (10 W/min). VO2, VCO2, and VE were 
measured throughout the test using an Aeromonitor AE-300s (Minato Medical Science, Osaka, 
Japan), as previously described [5]. Before the parameters from the respiratory gas analysis 
were calculated, breath-by-breath data were interpolated to give second-by-second values. 
These second-by-second values were then calculated as successive 3-second averages, and 
the averages were translated into a five-point moving average.  
The peak VO2 was calculated as the average values obtained during the last 15 
seconds of incremental exercise. The percentage of peak VO2 was calculated by dividing the 
measured peak VO2 by the predicted peak VO2. The predicted peak VO2 was determined 
based on a normal Japanese population [6]. The gas exchange ratio, which is equal to 
  
 
 
VCO2/VO2, was calculated during the last 15 seconds of incremental exercise. The VE-VCO2 
slope during incremental exercise was calculated by a method previously reported [7]. The 
end-tidal PCO2 (PETCO2) at rest was calculated as the average values obtained during the 4 
minutes of rest. The PETCO2 at peak exercise was calculated as the average of values 
obtained during the last 15 seconds of incremental exercise. 
The amplitude of the oscillating VE was calculated as the difference between the 
peak and nadir of the oscillating VE for each of the cycles noted from the beginning of 
warm-up exercise until the end of incremental exercise, and expressed as a mean value. The 
percentage amplitude was calculated by dividing the amplitude by the mean VE during each 
oscillation, and expressed as a mean value of all oscillations. The cycle length of the 
oscillating VE was calculated as the interval from the peak to the following peak of the 
oscillating VE for each of the cycles, and expressed as a mean value. The amplitude and cycle 
length of the oscillating VO2 and VCO2 were calculated by a similar approach. The 
oscillatory pattern of VO2 usually precedes VCO2 (Figure 1). Thus, the time difference 
between the peak of the oscillating VO2 and the corresponding peak of the oscillating VCO2 
(time from the peak of the oscillating VCO2 – time of the corresponding peak of the 
oscillating VO2) was calculated for each of the cycles and expressed as a mean value. A spiral 
phenomenon, defined as at least three consecutive counterclockwise changes in the 
VCO2-versus-VO2 plot (i.e., a movement from a left lower side to a right upper side, then 
slightly to a left upper side, and back to the left lower side, forming an ellipse), was visually 
identified (Figure 1, panel B for an example of the spiral pattern in a representative subject). 
  
 
 
The cardiopulmonary indices were compared between patients who manifested the spiral 
phenomenon and those who did not.  
 Data are presented as the mean ± SD. Intergroup differences for variables were 
compared by the unpaired t-test, or by the Fisher’s exact test where appropriate. Linear 
regression analysis was used to correlate the measured variables. All analyses were performed 
using SPSS version 19.0 software (SPSS Inc., Chicago, Illinois) for Windows (Microsoft 
Corporation, Redmond, Washington). A p value of less than 0.05 was considered statistically 
significant for all comparisons. 
 
RESULTS 
The peculiar spiral phenomenon was noted in the plots of VCO2 against VO2 
during CPX in 39% of the cardiac patients with oscillatory breathing. There were no 
significant differences in gender, age, height, weight, body mass index, or cardiac disease 
etiology between the patients with and without the spiral phenomenon, though idiopathic 
dilated cardiomyopathy was more frequent among the former (Table 1).  
Similar to the oscillating VE, clear oscillatory changes were noted in both the VO2 
and VCO2 in the study population overall. The amplitudes and cycle lengths of the VE, VO2, 
and VCO2 oscillations were all higher in the patients with the spiral phenomenon than in 
those without it (Table 2). The VO2 oscillations were found to precede the VCO2 oscillations 
in 95 of the 126 subjects. The VCO2 oscillations preceded the VO2 oscillations in only one 
subject, and only by a slight degree. No phase difference between the VO2 and VCO2 
  
 
 
oscillations was observed in the remaining 30 patients. The mean phase difference between 
the VO2 and VCO2 oscillations was 2.2±2.7 sec in both groups combined, and was 
significantly larger in the patients with the spiral phenomenon than in those without it 
(4.4±3.0 sec vs. 0.7±0.8 sec, p<0.001). The phase difference between the VCO2 and VE 
oscillations was 0.8±1.0 sec in both groups combined and did not differ between the two 
groups. 
The left ventricular ejection fraction (LVEF) measured by echocardiography was 
significantly lower in the patients with the spiral phenomenon than in the patients without the 
spiral phenomenon (Table 2). The level of brain natriuretic peptide (BNP), a parameter 
measured in 87 out of the 126 patients, was significantly higher in the patients with the spiral 
phenomenon than in those without it. Meanwhile, the patients with the spiral phenomenon 
had a significantly lower peak VO2. The VE-VCO2 slope was significantly higher in the 
patients with the spiral phenomenon than in those without it. PETCO2 both at rest and at peak 
exercise was significantly lower in the patients with the spiral phenomenon than in those 
without it.  
Figure 2 shows the relation between cardiopulmonary indices and the cycle length of 
the VO2 oscillations. The cycle length of the VO2 oscillations showed significant positive 
correlations with the BNP and VE-VCO2 slope, and significant negative correlations with the 
LVEF and peak VO2. Figure 3 shows the relation between cardiopulmonary indices and phase 
difference between the VO2 and VCO2 oscillations. The phase difference showed significant 
positive correlations with the BNP and VE-VCO2 slope, and significant negative correlations 
  
 
 
with the LVEF and peak VO2.  
 
DISCUSSION 
In the present study we investigated the clinical significance of the spiral 
phenomenon in the VCO2-versus-VO2 plot recorded during CPX in patients with oscillatory 
breathing. According to our experiments, 39% of the cardiac patients with oscillatory 
breathing manifested the spiral phenomenon during exercise. The amplitudes of VO2 and 
VCO2 oscillations were higher and the phase difference between VO2 and VCO2 oscillations 
was longer and in the patients with the spiral phenomenon than in those without it. The 
patients with the spiral phenomenon exhibited a lower LVEF, higher BNP, lower peak VO2, 
higher VE-VCO2 slope, and lower PETCO2 than the patients without the spiral phenomenon. 
The patients with the spiral phenomenon also exhibited the lower heart rate and lower systolic 
blood pressure at peak exercise, suggesting lower cardiac output during exercise in these 
patients. Judging from these findings, we concluded that the spiral phenomenon was related 
to cardiopulmonary dysfunction and could be directly attributed both to the phase difference 
between the VO2 and VCO2 and to the higher amplitudes of the VO2 and VCO2 oscillations. 
The VE-VCO2 slope relates mainly to a ventilation/perfusion (V/Q) mismatch, and 
progressively steepens in patients with heart failure of worsening severity resulting from 
either systolic or diastolic dysfunction [8,9]. In patients with left ventricular dysfunction, as 
the hypo-perfusion to the lung caused by reduced pulmonary blood flow exacerbates the V/Q 
mismatch (high V/Q), leading to progressively lower PETCO2 as the cardiac disease worsens 
  
 
 
[1,10,11]. The lower peak VO2, higher VE-VCO2 slope, and lower PETCO2 observed in 
patients with the spiral phenomenon suggest that the cardiopulmonary dysfunction is more 
advanced in these patients than in the patients without the spiral phenomenon. 
 Instability of the respiratory control system is believed to be a major cause of not 
only central sleep apnea, but also oscillatory breathing during exercise. In 1994, Yajima et al. 
[12] reported that cardiac patients with oscillatory breathing present oscillatory changes in 
LVEF with a similar cyclical nature. Since then, fluctuation of the pulmonary blood flow has 
been proposed as another possible mechanism underlying oscillatory breathing [5,12,13]. 
VO2 oscillation, a phenomenon reflective of a change of pulmonary blood flow, preceded the 
VCO2 and VE oscillations in most of the subjects in our study. If the VE changes primarily 
due to a stimulus from the central nervous system to the respiratory muscles, the change of 
VE must precede the change of VO2. Our findings may therefore further support the central 
hypothesis, namely, that fluctuations in the pulmonary blood flow produce oscillatory 
breathing.  
The spiral phenomenon in the VCO2-versus-VO2 plot probably derives from both the 
high amplitudes of the VO2 and VCO2 oscillations and the longer phase difference between 
the oscillations. The VCO2 kinetics is reported to be slower than the VO2 kinetics during the 
onset of exercise [14,15], although the mechanisms responsible for the phase difference 
between the VO2 and VCO2 kinetics are complicated and still undetermined. During mild to 
moderate exercise, ventilation normally increases at the rate required to remove the additional 
CO2 generated in order to keep the arterial PCO2 and pH close to their resting values [2,15]. 
  
 
 
Thus, the VE kinetics is usually closely related to the VCO2 kinetics during exercise [15]. 
And this, in turn, suggests that the phase difference between the VO2 and VCO2 oscillations 
probably stems not only from the prolonged physiological delay of the VCO2 kinetics, but 
also from the delay of the ventilatory response to the fluctuations of the pulmonary CO2 flow. 
The latter, in particular, may relate to prolonged circulation time which is known to increase 
with the severity of heart failure. 
 There are several limitations in this study. The BNP was obtained only in 87 out of 
126 patients in the present study. Our criterion for enrolling subjects with oscillatory 
breathing was at least three consecutive cycles with an amplitude of greater than 25%. The 
frequency of the spiral phenomenon in cardiac patients depends on the specific definition 
used for determining the oscillatory breathing, as well as the severity and/or etiology of 
cardiac disease in the study population. While β-blockers, diuretics, and digitalis were 
prescribed more frequently in the patients with spiral phenomenon, we could not clearly 
determine whether one or more of these medications diminished or enhanced the spiral 
phenomenon. We could not perform a subgroup analysis stratified by heart failure in patients 
with preserved versus reduced LVEF. We also do not know the relation between the spiral 
phenomenon and diastolic LV function. A larger study population would be necessary to 
clarify these issues. Among 2,263 patients who were screened for oscillatory breathing, the 
exercise tests of 102 patients (4.5%) were prematurely stopped due to adverse signs or 
symptoms, potentially precluding them from attaining maximum effort.  
 To our knowledge, this is the first report linking the mechanisms and clinical 
  
 
 
significance of the spiral phenomenon in the VCO2-versus-VO2 plot in cardiac patients. Our 
findings indicate that the spiral phenomenon is a novel marker of cardiopulmonary 
dysfunction during exercise. We believe that the spiral phenomenon can be used to stratify 
patients with heart failure, although long term follow-up and additional prognostic studies are 
needed to establish the clinical role of this phenomenon.  
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FIGURE LEGENDS 
 
Figure 1. Panel A: Changes in the O2 uptake (VO2), CO2 output (VCO2), and gas exchange 
ratio (R) during cardiopulmonary exercise testing in a patient with the spiral 
phenomenon. Panel B: VCO2-versus-VO2 plot produced from the data of panel A. 
Panel C: Changes in VO2, VCO2, and R during cardiopulmonary exercise testing 
in a patient without the spiral phenomenon. Panel D: VCO2-versus-VO2 plot 
produced from the data of panel C.  
 
Figure 2. Brain natriuretic peptide (BNP) (panel A), left ventricular ejection fraction (LVEF) 
(panel B), peak O2 uptake (VO2) (panel C), and slope of the increase in ventilation 
versus the increase in CO2 output (VE-VCO2 slope) (panel D) plotted against the 
cycle length of VO2 oscillations.  
 
Figure 3. Brain natriuretic peptide (BNP) (panel A), left ventricular ejection fraction (LVEF) 
(panel B), peak O2 uptake (VO2) (panel C), and slope of the increase in ventilation 
versus the increase in CO2 output (VE-VCO2 slope) (panel D) plotted against the 
phase difference between VO2 and VCO2 oscillations. 
  
  
 
 
Table 1. Patient characteristics in patients with and without a spiral phenomenon  
         
 All patients A Spiral Phenomenon  
Characteristics  YES NO p value 
  (n = 126) (n = 49) (n = 77)   
Male/female 103 / 23 42 / 7 61 / 16 NS 
Age (years) 63 ± 12 65 ± 11 61 ± 13 NS 
Height (cm) 166 ± 8 165 ± 8 167 ± 9 NS 
Weight (kg) 65 ± 13 65 ± 13 65 ± 12 NS 
Body mass index (kg/m2) 24 ± 4 24 ± 4 23 ± 4 NS 
Etiology     
      Valvular disease 35 (28%) 14 (29%) 21 (27%) NS 
      Coronary artery disease 35 (28%) 12 (24%) 23 (30%) NS 
      Idiopathic dilated cardiomyopathy 20 (16%) 12 (24%) 8 (10%) 0.035  
      Hypertrophic cardiomyopathy 10 (8%) 2 (4%) 8 (10%) NS 
      Other cardiac disease  26 (21%) 9 (18%) 17 (22%) NS 
Medication     
     β-blockers 82 (65%) 40 (82%) 42 (55%) 0.002  
     ACEI/ARB 67 (53%) 26 (53%) 41 (53%) NS 
     Diuretics 62 (49%) 32 (65%) 30 (39%) 0.004  
     Ca-channel blockers 33 (26%) 10 (20%) 23 (30%) NS 
     Nitrates 20 (16%) 9 (18%) 11 (14%) NS 
     Digitalis 7 (6%) 7 (14%) 0 0.001  
Data are presented as the mean ± SD.  
ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker;  
NS, not significant.     
 
  
  
 
 
 
Table 2. Patient characteristics in patients with and without a spiral phenomenon 
  
 
        
 All patients A Spiral Phenomenon  
Characteristics  YES NO p value 
  (n = 126) (n = 49) (n = 77)   
At rest     
     Creatinine (mg/dL) 1.1 ± 0.8 1.3 ± 1.2 0.9 ± 0.3 0.039 
     Brain natriuretic peptide (pg/mL) 398 ± 558 637 ± 698 228 ± 351 0.002 
     Left ventricular ejection fraction (%) 52 ± 20 43 ± 21 57 ± 17 <0.001 
     Left ventricular diastolic dimension (mm) 54 ± 12 59 ± 14 51 ± 9 0.001 
     Left ventricular systolic dimension (mm) 40 ± 15 47 ± 17 36 ± 12 <0.001 
     Heart rate (beats/min) 75 ± 16 76 ± 16 75 ± 15 NS 
     Systolic blood pressure (mmHg) 115 ± 24 109 ± 26 119 ± 22 0.018 
     Diastolic blood pressure (mmHg) 73 ± 15 71 ± 16 75 ± 14 NS 
     End-tidal PCO2 (mmHg) 32 ± 4 31 ± 4 33 ± 4 0.007 
At peak exercise     
     Heart rate (beats/min) 125 ± 33 117 ± 29 130 ± 35 0.026 
     Systolic blood pressure (mmHg) 163 ± 38 149 ± 42 172 ± 33 0.001 
     Diastolic blood pressure (mmHg) 81 ± 20 80 ± 21  82 ± 19  NS 
     End-tidal PCO2 (mmHg) 35 ± 5 33 ± 5 36 ± 5 0.001 
     Gas exchange ratio 1.10 ± 0.10 1.09 ± 0.11 1.11 ± 0.09 NS 
     Peak VO2 (mL/min/kg) 16.7 ± 6.3 14.5 ± 5.6 18.1 ± 6.3 0.002 
     Peak VO2 (%) 67 ± 23 60 ± 23 72 ± 21 0.006 
VE-VCO2 slope 36 ± 9 40 ± 10 34 ± 7 <0.001 
Amplitude of VE (L/min)  6.3 ± 2.2  7.5 ± 2.5  5.6 ± 1.7 <0.001 
Amplitude of VE (%)  38 ± 13  45 ± 15  34 ± 10 <0.001 
Cycle length of VE (sec)  57 ± 16  65 ± 19  51 ± 12 <0.001 
Amplitude of VO2 (mL/min)  186 ± 64  203 ± 70  176 ± 58 0.023 
Amplitude of VO2 (%)  46 ± 16  52 ± 19  42 ± 13 0.002 
Cycle length of VO2 (sec)  56 ± 16  65 ± 17  51 ± 11 <0.001 
Amplitude of VCO2 (mL/min)  168 ± 56  187 ± 57  155 ± 52 0.002 
Amplitude of VCO2 (%)  46 ± 16  53 ± 18  41 ± 14 <0.001 
Cycle length of VCO2 (sec)  56 ± 17  65 ± 19  51 ± 11 <0.001 
Phase difference between VO2 and VCO2 (sec)  2.2 ± 2.7   4.4 ± 3.0  0.7 ± 0.8 <0.001 
The brain natriuretic peptide was obtained in 87 patients (36 patients with a spiral phenomenon and 51 patients without it). 
Data are presented as the mean ± SD.     
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0
100
200
300
400
500
600
700
800
0 120 240 360 480
Phase difference  
between VO2 and VCO2 Amplitude of VO2 
Cycle length of VO2 
Warm-up (0W) Incremental exercise (10W/min) 
Time (sec) 
A 
0
200
400
600
800
0 200 400 600 800
VCO2 (mL/min) 
VO2 (mL/min) 
B 
0
200
400
600
800
1000
1200
0 200 400 600 800 1000 1200
VCO2 (mL/min) 
VO2 (mL/min) 
D 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0
200
400
600
800
1000
1200
0 120 240 360 480 600 720
Warm-up (0W) Incremental exercise (10W/min) 
Time (sec) 
C 
Figure 1 
VO2, VCO2 (mL/min) 
VO2, VCO2 (mL/min) 
R 
R 
R 
VCO2 
VO2 
R 
VCO2 
VO2 
0 
500 
1000 
1500 
2000 
2500 
3000 
3500 
0 20 40 60 80 100 120 
B
N
P
 (
p
g
/m
L
) 
Cycle length of VO2 oscillation (sec) 
r=0.507 
p<0.001 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
0 20 40 60 80 100 120 
L
V
E
F
 (
%
) 
Cycle length of VO2 oscillation (sec) 
r=-0.476 
p<0.001 
0 
10 
20 
30 
40 
0 20 40 60 80 100 120 
P
ea
k
 V
O
2
 (
m
L
/m
in
/k
g
) 
Cycle length of VO2 oscillation (sec) 
r=-0.392 
p<0.001 
0 
10 
20 
30 
40 
50 
60 
70 
0 20 40 60 80 100 120 
V
E
-V
C
O
2
 s
lo
p
e 
Cycle length of VO2 oscillation (sec) 
r=0.546 
p<0.001 
Figure 2 
With a spiral phenomenon 
Without a spiral phenomenon 
A B 
C D 
0 
500 
1000 
1500 
2000 
2500 
3000 
3500 
-2 0 2 4 6 8 10 12 14 
B
N
P
 (
p
g
/m
L
) 
Phase difference between VO2 and VCO2 (sec) 
r=0.558 
p<0.001 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
-2 0 2 4 6 8 10 12 14 
L
V
E
F
 (
%
) 
Phase difference between VO2 and VCO2 (sec) 
r=-0.369 
p<0.001 
0 
10 
20 
30 
40 
-2 0 2 4 6 8 10 12 14 
P
ea
k
 V
O
2
 (
m
L
/m
in
/k
g
) 
Phase difference between VO2 and VCO2 (sec) 
r=-0.382 
p<0.001 
0 
10 
20 
30 
40 
50 
60 
70 
-2 0 2 4 6 8 10 12 14 
V
E
-V
C
O
2
 s
lo
p
e 
Phase difference between VO2 and VCO2 (sec) 
r=0.583 
p<0.001 
Figure 3 
With a spiral phenomenon 
Without a spiral phenomenon 
A B 
C D 
